Mei Wang is an Honorary Joint Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore, and an Assistant Professor at Duke-NUS Graduate Medical School. Her research focuses on the role of protein prenylation in cancer development, particularly the modification of Ras and Rho oncoproteins via the CAAX motif. By targeting key enzymes such as isoprenylcysteine carboxyl methyltransferase (Icmt) and geranylgeranyltransferase I (GGTase-I), her lab investigates how disrupting prenylation affects oncogenic signaling, induces autophagy, and promotes cancer cell death. Her work has shown that Icmt inhibition triggers autophagy-mediated cell death and G1 cell cycle arrest, with potential therapeutic implications. Beyond mechanistic studies, her group is also advancing small-molecule inhibitors into preclinical development, evaluating their efficacy, pharmacokinetics, and toxicity in collaboration with NUS colleagues. Her research bridges fundamental cancer biology with translational applications, offering promising avenues for the development of novel cancer therapies.